Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales : an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol

Authors:

Abstract
Background and objectives: Carbapenem-resistant Enterobacterales (CRE) that do not produce carbapenemases (non-CPE) are increasingly reported worldwide and represent a major therapeutic challenge. These strains are typically resistant to carbapenems due to the combined effects of ESBL and/or AmpC production and reduced outer membrane permeability. However, data on their susceptibility to new antibiotics and β-lactam/β-lactamase inhibitor (BL/BLI) combinations remain limited. This study aimed to evaluate the in vitro activity of new antibiotics and BL/BLI combinations against CR non-CPE isolates. Methods: MICs of ceftazidime–avibactam, cefepime–enmetazobactam, cefepime–taniborbactam, cefepime–zidebactam, imipenem–relebactam, meropenem–vaborbactam, aztreonam–avibactam, and cefiderocol were determined by the broth microdilution for 151 CR non-CPE isolates collected between 2024 and January 2025 at the French National Reference Center. The collection included ESBL producers (n = 33), AmpC producers (n = 79), and ESBL/AmpC co-producers (n = 29). Results: Overall susceptibility rates were as follows: cefepime–zidebactam (97.4%), aztreonam–avibactam (92.7%), ceftazidime–avibactam (91.4%), meropenem–vaborbactam (91.3%), imipenem–relebactam (88.7%), cefiderocol (86.8%), cefepime–taniborbactam (82.1%), and cefepime–enmetazobactam (68.9%). Susceptibility varied according to the resistance mechanisms. Among ESBL producers, CTX-M-33-producing strains exhibited higher MICs than CTX-M-15 producers. Among AmpC producers, no specific high-risk AmpC type was associated with higher MICs, but Klebsiella aerogenes isolates exposed higher MICs than Enterobacter cloacae complex isolates. Conclusions: CR non-CPE exhibit heterogeneous resistance profiles, especially in ESBL/AmpC co-producers and CTX-M-33-producing isolates. While cefepime–zidebactam, imipenem–relebactam, and cefiderocol were the most active agents, susceptibility testing remains essential to guide therapy in this emerging and neglected bacterial group.
Funding Information
  • Advanz Pharma

This publication has 29 references indexed in Scilit: